Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | ATM | Q13315 | 2/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24574681 | 0.97 | KDM4E (0.41) | KDM4EALDH1A1POLBNPC1RAB9A | |
| SCHEMBL17190473 | 0.85 | KDM4E (0.32) | KDM4EALDH1A1 | |
| SCHEMBL24925897 | 0.82 | HTT (0.39) | KDM4EALDH1A1POLBPKMHTT | |
| SCHEMBL21553936 | 0.76 | PTGS2 (0.44) | ALDH1A1HPGD | |
| SCHEMBL25795858 | 0.75 | KDM4E (0.41) | KDM4EALDH1A1POLBNPC1RAB9A | |
| SCHEMBL24925896 | 0.73 | GAA (0.38) | KDM4EALDH1A1POLBHTTHPGD | |
| SCHEMBL22815305 | 0.71 | TSHR (0.36) | — | |
| SCHEMBL21140438 | 0.71 | DRD4 (0.32) | KDM4ENOS3NOS1NOS2 | |
| SCHEMBL25771775 | 0.71 | DRD4 (0.32) | KDM4ENOS3NOS1NOS2 | |
| SCHEMBL25795855 | 0.71 | DRD4 (0.32) | KDM4ENOS3NOS1NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3983020-B1 | AGENTS FOR CLEAVING LABELS FROM BIOMOLECULES IN VIVO | TAGWORKS PHARMACEUTICALS B V (NL) | 2024-06-26 | — | — | EP | disclosed |
| EP-3788032-B1 | COMPOUNDS COMPRISING A LINKER FOR INCREASING TRANSCYCLOOCTENE STABILITY | TAGWORKS PHARMACEUTICALS B V (NL) | 2024-01-24 | — | — | EP | disclosed |
| EP-4245744-A2 | CHEMICALLY CLEAVABLE GROUP | Tagworks Pharmaceuticals B.V. (NL) | 2023-09-20 | — | — | EP | disclosed |
| EP-2922574-B1 | CHEMICALLY CLEAVABLE GROUP | TAGWORKS PHARMACEUTICALS B V (NL) | 2023-05-17 | — | — | EP | disclosed |
| US-20230121556-A1 | COMPOUNDS FOR FAST AND EFFICIENT CLICK RELEASE | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2023-04-20 | — | — | US | disclosed |
| US-20210308207-A1 | COMPOUNDS COMPRISING A LINKER FOR INCREASING TRANSCYCLOOCTENE STABILITY | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2021-10-07 | — | — | US | disclosed |
| US-20210299286-A1 | TETRAZINES FOR HIGH CLICK CONJUGATION YIELD IN VIVO AND HIGH CLICK RELEASE YIELD | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2021-09-30 | — | — | US | disclosed |
| US-10927139-B2 | Chemically cleavable group | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2021-02-23 | — | — | US | disclosed |
| US-20210002320-A1 | CHEMICALLY CLEAVABLE GROUP | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2021-01-07 | — | — | US | disclosed |
| WO-2020256546-A1 | COMPOUNDS FOR FAST AND EFFICIENT CLICK RELEASE | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2020-12-24 | — | — | WO | disclosed |
| WO-2020256544-A1 | TETRAZINES FOR HIGH CLICK RELEASE SPEED AND YIELD | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2020-12-24 | — | — | WO | disclosed |
| WO-2020256545-A1 | AGENTS FOR CLEAVING LABELS FROM BIOMOLECULES IN VIVO | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2020-12-24 | — | — | WO | disclosed |
| US-20170143840-A1 | BIO-ORTHOGONAL DRUG ACTIVATION | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2017-05-25 | — | — | US | disclosed |
| US-9421274-B2 | Bio-orthogonal drug activation | KONINKLIJKE PHILIPS N.V. (NL) | 2016-08-23 | — | — | US | disclosed |
| US-20160106859-A1 | BIO-ORTHOGONAL DRUG ACTIVATION | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2016-04-21 | — | — | US | disclosed |
| US-20150344514-A1 | CHEMICALLY CLEAVABLE GROUP | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2015-12-03 | — | — | US | disclosed |
| US-20150344514-A1 | CHEMICALLY CLEAVABLE GROUP | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2015-12-03 | — | — | US | disclosed |
| US-20150297741-A1 | BIO-ORTHOGONAL DRUG ACTIVATION | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2015-10-22 | — | — | US | disclosed |
| WO-2014081301-A1 | BIO-ORTHOGONAL DRUG ACTIVATION | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2014-05-30 | — | — | WO | disclosed |
| WO-2014081303-A1 | CHEMICALLY CLEAVABLE GROUP | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2014-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170143840-A1 | BIO-ORTHOGONAL DRUG ACTIVATION | JMJD7, KIT, PAICS | KDM4E 1403/4885ALDH1A1 935/4885POLB 2540/4885 |
| US-20210002320-A1 | CHEMICALLY CLEAVABLE GROUP | SQLE, CTRL, ENO1 | KDM4E 4285/4885ALDH1A1 718/4885POLB 1691/4885 |
| US-20150344514-A1 | CHEMICALLY CLEAVABLE GROUP | SQLE, CTRL, ENO1 | KDM4E 4100/4885ALDH1A1 780/4885POLB 1630/4885 |
| US-10927139-B2 | Chemically cleavable group | SQLE, CTRL, ENO1 | KDM4E 4100/4885ALDH1A1 780/4885POLB 1630/4885 |
| US-20230121556-A1 | COMPOUNDS FOR FAST AND EFFICIENT CLICK RELEASE | LTB4R, LTC4S, LTA4H | KDM4E 1583/4885ALDH1A1 879/4885POLB 3205/4885 |
| US-20150297741-A1 | BIO-ORTHOGONAL DRUG ACTIVATION | KIT, JMJD7, TPSB2 | KDM4E 2952/4885ALDH1A1 1711/4885POLB 2718/4885 |
| US-20160106859-A1 | BIO-ORTHOGONAL DRUG ACTIVATION | JMJD7, KIT, PAICS | KDM4E 1403/4885ALDH1A1 935/4885POLB 2540/4885 |
| US-20210299286-A1 | TETRAZINES FOR HIGH CLICK CONJUGATION YIELD IN VIVO AND HIGH CLICK RELEASE YIELD | FCER2, SQLE, TTL | KDM4E 3967/4885ALDH1A1 1600/4885POLB 4302/4885 |
| US-20210308207-A1 | COMPOUNDS COMPRISING A LINKER FOR INCREASING TRANSCYCLOOCTENE STABILITY | VIP, PIN1, QPCT | KDM4E 4319/4885ALDH1A1 4815/4885POLB 3563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.